Ultragenyx Pharmaceutical Company Profile (NASDAQ:RARE)

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical logoUltragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. Recombinant human beta-glucuronidase (rhGUS), is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7 (MPS 7). It is developing UX007 for oral administration intended as a substrate replacement therapy. It is developing aceneuramic acid extended-release (Ace-ER) for the treatment of GNE myopathy.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RARE
  • CUSIP:
Key Metrics:
  • Previous Close: $76.92
  • 50 Day Moving Average: $73.16
  • 200 Day Moving Average: $70.87
  • 52-Week Range: $46.52 - $86.77
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -12.22
  • P/E Growth: -0.37
  • Market Cap: $3.19B
  • Outstanding Shares: 40,859,000
  • Beta: 1.83
Profitability:
  • Return on Equity: -46.68%
  • Return on Assets: -43.12%
Debt:
  • Current Ratio: 8.26%
  • Quick Ratio: 8.26%
Additional Links:
Companies Related to Ultragenyx Pharmaceutical:

Analyst Ratings

Consensus Ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) (?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 12 Buy Ratings
Consensus Rating:Buy (Score: 2.79)
Consensus Price Target: $92.25 (18.00% upside)

Analysts' Ratings History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Show:
DateFirmActionRatingPrice TargetDetails
2/17/2017Cowen and CompanyReiterated RatingBuyView Rating Details
2/17/2017WedbushInitiated CoverageOutperform$88.00View Rating Details
2/17/2017Jefferies Group LLCReiterated RatingBuy$109.00View Rating Details
11/30/2016Citigroup Inc.DowngradeNeutral -> SellView Rating Details
11/30/2016Piper Jaffray CompaniesReiterated RatingBuy$96.00View Rating Details
11/14/2016Leerink SwannReiterated RatingOutperform$94.00 -> $90.00View Rating Details
11/11/2016Canaccord GenuitySet Price TargetBuy$103.00View Rating Details
11/9/2016J P Morgan Chase & CoReiterated RatingBuy$106.00View Rating Details
9/25/2016HC WainwrightReiterated RatingBuy$102.00 -> $109.00View Rating Details
9/14/2016Credit Suisse GroupReiterated RatingBuy$101.00View Rating Details
7/18/2016Robert W. BairdReiterated RatingOutperform$85.00View Rating Details
6/28/2016Bank of America CorpInitiated CoverageBuy$72.00View Rating Details
6/8/2016Morgan StanleyReiterated RatingHoldView Rating Details
6/8/2016JMP SecuritiesReiterated RatingBuy$80.00 -> $84.00View Rating Details
2/9/2016Sterne Agee CRTInitiated CoverageBuyView Rating Details
12/1/2015Stifel NicolausInitiated CoverageBuy -> Buy$125.00 -> $125.00View Rating Details
8/31/2015Raymond James Financial, Inc.Initiated CoverageOutperform$125.00View Rating Details
7/13/2015SunTrust Banks, Inc.Boost Price TargetBuy$82.00 -> $119.00View Rating Details
3/30/2015MLV & Co.Initiated CoverageBuy$79.00View Rating Details
3/24/2015CRT CapitalInitiated CoverageBuy$90.00View Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2017        
2/16/2017Q4 2016($1.72)($1.75)$0.05 million$0.01 millionViewN/AView Earnings Details
11/7/2016Q3($1.53)($1.64)$1.16 millionViewListenView Earnings Details
8/8/2016Q2($1.44)($1.46)ViewN/AView Earnings Details
5/9/2016Q1($1.29)($1.35)ViewN/AView Earnings Details
2/25/2016Q4($1.14)($1.42)ViewListenView Earnings Details
11/9/2015Q3($0.87)($1.03)ViewN/AView Earnings Details
8/13/2015Q215($0.63)($0.83)ViewListenView Earnings Details
5/11/2015Q1 15($0.54)($0.63)ViewListenView Earnings Details
3/25/2015Q414($0.53)($0.52)ViewListenView Earnings Details
11/10/2014Q314($0.46)($0.50)ViewN/AView Earnings Details
8/11/2014Q214($0.42)($0.45)ViewN/AView Earnings Details
5/12/2014Q114($0.37)($0.85)ViewN/AView Earnings Details
3/24/2014($0.38)($4.98)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Current Year EPS Consensus Estimate: $-7.06 EPS
Next Year EPS Consensus Estimate: $-6.40 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($1.38)($1.13)($1.26)
Q2 20164($1.59)($1.13)($1.39)
Q3 20164($1.55)($1.51)($1.53)
Q4 20164($1.86)($1.69)($1.76)
Q1 20174($1.82)($1.71)($1.77)
Q2 20174($1.93)($1.70)($1.82)
Q3 20174($2.01)($1.69)($1.87)
Q4 20174($2.09)($1.67)($1.88)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Insider Ownership Percentage: 10.10%
Institutional Ownership Percentage: 96.35%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/5/2016William AliskiDirectorSell6,000$78.19$469,140.00View SEC Filing  
11/9/2016Shalini SharpCFOSell24,000$71.20$1,708,800.00View SEC Filing  
10/19/2016Shalini SharpCFOSell12,000$61.40$736,800.00View SEC Filing  
10/14/2016Emil D KakkisCEOSell20,000$63.02$1,260,400.00View SEC Filing  
8/15/2016Emil D KakkisCEOSell20,000$67.61$1,352,200.00View SEC Filing  
7/21/2016Sunil AgarwalInsiderSell649$52.68$34,189.32View SEC Filing  
7/15/2016Emil D KakkisCEOSell20,000$50.85$1,017,000.00View SEC Filing  
6/20/2016Sunil AgarwalInsiderSell650$54.16$35,204.00View SEC Filing  
5/24/2016Sunil AgarwalInsiderSell650$66.00$42,900.00View SEC Filing  
5/16/2016Emil D KakkisCEOSell20,000$59.95$1,199,000.00View SEC Filing  
4/20/2016Sunil AgarwalInsiderSell649$70.53$45,773.97View SEC Filing  
4/15/2016Emil D KakkisCEOSell20,000$70.33$1,406,600.00View SEC Filing  
3/22/2016Sunil AgarwalInsiderSell650$61.45$39,942.50View SEC Filing  
2/22/2016Sunil AgarwalInsiderSell658$63.48$41,769.84View SEC Filing  
1/20/2016Sunil AgarwalinsiderSell585$72.83$42,605.55View SEC Filing  
12/31/2015Emil D. KakkisCEOSell20,000$114.52$2,290,400.00View SEC Filing  
12/22/2015Sunil AgarwalInsiderSell498$114.81$57,175.38View SEC Filing  
12/18/2015Theodore Alan HuizengainsiderSell1,500$110.55$165,825.00View SEC Filing  
8/20/2015Sunil AgarwalinsiderSell17,020$111.18$1,892,283.60View SEC Filing  
8/12/2015Thomas Richard KassbergSVPSell3,334$109.70$365,739.80View SEC Filing  
7/20/2015Shalini SharpCFOSell3,854$131.95$508,535.30View SEC Filing  
7/8/2015Thomas Richard KassbergSVPSell3,334$102.12$340,468.08View SEC Filing  
6/18/2015Shalini SharpCFOSell4,000$96.08$384,320.00View SEC Filing  
6/17/2015Theodore Alan HuizengaInsiderSell1,500$94.80$142,200.00View SEC Filing  
6/10/2015Thomas Richard KassbergSVPSell3,334$88.19$294,025.46View SEC Filing  
4/20/2015Shalini SharpCFOSell4,000$62.23$248,920.00View SEC Filing  
4/8/2015Thomas Richard KassbergSVPSell3,333$58.02$193,380.66View SEC Filing  
1/20/2015Shalini SharpCFOSell4,000$51.24$204,960.00View SEC Filing  
12/18/2014Shalini SharpCFOSell4,000$44.82$179,280.00View SEC Filing  
12/10/2014Thomas Richard KassbergSVPSell3,333$40.22$134,053.26View SEC Filing  
12/4/2014William AliskiDirectorSell6,000$42.16$252,960.00View SEC Filing  
11/20/2014Shalini SharpCFOSell4,000$44.07$176,280.00View SEC Filing  
11/12/2014Thomas Richard KassbergSVPSell3,333$41.85$139,486.05View SEC Filing  
10/8/2014Thomas Richard KassbergSVPSell3,333$53.26$177,515.58View SEC Filing  
9/18/2014Shalini SharpCFOSell4,000$56.00$224,000.00View SEC Filing  
9/10/2014Thomas Richard KassbergSVPSell3,333$54.82$182,715.06View SEC Filing  
9/3/2014Thomas Richard KassbergSVPSell20,000$53.91$1,078,200.00View SEC Filing  
8/18/2014Shalini SharpCFOSell4,000$53.97$215,880.00View SEC Filing  
7/14/2014Group Holdings (Sbs) Advis TpgInsiderSell488,820$37.60$18,379,632.00View SEC Filing  
1/31/2014Fmr LlcInsiderBuy175,000$21.00$3,675,000.00View SEC Filing  
1/30/2014Shalini SharpCFOBuy4,500$21.00$94,500.00View SEC Filing  
1/30/2014Thomas Richard KassbergSVPBuy1,500$21.00$31,500.00View SEC Filing  
1/30/2014William AliskiDirectorBuy5,000$21.00$105,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ultragenyx Pharmaceutical (NASDAQ:RARE)
DateHeadline
News IconWatching the Charts on Shares of Ultragenyx Pharmaceutical Inc (RARE) - Baxter Review (NASDAQ:RARE)
baxternewsreview.com - February 23 at 8:37 AM
News IconAre Analysts Optimistic About Where Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is Heading? - Winfield Review (NASDAQ:RARE)
winfieldreview.com - February 23 at 8:37 AM
finance.yahoo.com logoULTRAGENYX PHARMACEUTICAL INC. Financials (NASDAQ:RARE)
finance.yahoo.com - February 22 at 7:36 PM
finance.yahoo.com logoBaron Opportunity Fund Comments on Ultragenyx Pharmaceutical (NASDAQ:RARE)
finance.yahoo.com - February 21 at 5:24 PM
News IconInvestor Watch on Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Davidson Register (NASDAQ:RARE)
davidsonregister.com - February 18 at 8:12 AM
marketexclusive.com logoULTRAGENYX PHARMACEUTICAL INC. (NASDAQ:RARE) Files An 8-K Results of Operations and Financial Condition (NASDAQ:RARE)
marketexclusive.com - February 17 at 8:00 PM
finance.yahoo.com logoEdited Transcript of RARE earnings conference call or presentation 16-Feb-17 10:00pm GMT (NASDAQ:RARE)
finance.yahoo.com - February 17 at 8:00 PM
biz.yahoo.com logoULTRAGENYX PHARMACEUTICAL INC. Files SEC form 10-K, Annual Report (NASDAQ:RARE)
biz.yahoo.com - February 17 at 8:00 PM
4-traders.com logoUltragenyx Pharmaceutical : reports 4Q loss (NASDAQ:RARE)
www.4-traders.com - February 16 at 7:04 PM
biz.yahoo.com logoQ4 2016 Ultragenyx Pharmaceutical Inc Earnings Release - After Market Close (NASDAQ:RARE)
us.rd.yahoo.com - February 16 at 7:04 PM
biz.yahoo.com logoQ4 2016 Ultragenyx Pharmaceutical Inc Earnings Release - After Market Close (NASDAQ:RARE)
us.rd.yahoo.com - February 16 at 7:04 PM
biz.yahoo.com logoQ4 2016 Ultragenyx Pharmaceutical Inc Earnings Release - After Market Close (NASDAQ:RARE)
us.rd.yahoo.com - February 16 at 7:04 PM
us.rd.yahoo.com logoUltragenyx Reports Fourth Quarter and Full Year 2016 Financial Results and Corporate Update (NASDAQ:RARE)
us.rd.yahoo.com - February 16 at 7:04 PM
us.rd.yahoo.com logoUltragenyx Reports Fourth Quarter and Full Year 2016 Financial Results and Corporate Update (NASDAQ:RARE)
us.rd.yahoo.com - February 16 at 7:04 PM
biz.yahoo.com logoULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement (NASDAQ:RARE)
us.rd.yahoo.com - February 16 at 7:04 PM
sg.finance.yahoo.com logoUltragenyx reports 4Q loss (NASDAQ:RARE)
sg.finance.yahoo.com - February 16 at 7:04 PM
sg.finance.yahoo.com logoUltragenyx reports 4Q loss (NASDAQ:RARE)
sg.finance.yahoo.com - February 16 at 7:04 PM
sg.finance.yahoo.com logoUltragenyx reports 4Q loss (NASDAQ:RARE)
sg.finance.yahoo.com - February 16 at 7:04 PM
News IconShares in the Spotlight: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Baldwin Journal (NASDAQ:RARE)
baldwinjournal.com - February 15 at 12:23 AM
globenewswire.com logoUltragenyx to Present at Leerink Partners Global Healthcare Conference - GlobeNewswire (press release) (NASDAQ:RARE)
globenewswire.com - February 12 at 8:23 AM
feeds.benzinga.com logoUltragenyx to Present at Leerink Partners Global Healthcare Conference (NASDAQ:RARE)
feeds.benzinga.com - February 10 at 9:34 AM
finance.yahoo.com logoUltragenyx to Host Conference Call for Fourth Quarter and Full Year 2016 Financial Results and Corporate Update (NASDAQ:RARE)
finance.yahoo.com - February 9 at 10:49 PM
capitalcube.com logoUltragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : RARE-US : February 1, 2017 (NASDAQ:RARE)
www.capitalcube.com - February 1 at 10:43 PM
News IconStocks Wilt on Friday But Pull Off Positive Week, How Did This One Fare: Ultragenyx Pharmaceutical Inc. (NASDAQ ... - Wall Street Beacon (NASDAQ:RARE)
wsbeacon.com - January 30 at 8:07 AM
News IconTrading Monitor: Focusing in on Shares of Ultragenyx Pharmaceutical Inc. (RARE) - Market Point (NASDAQ:RARE)
mtptnews.com - January 30 at 12:54 AM
News IconUltragenyx Pharmaceutical In (RARE) Shares Rose While Iguana Healthcare Management LLC Raised by $4.20 Million Its Stake (NASDAQ:RARE)
randolphguide.com - January 26 at 2:33 AM
News IconLooking Ahead for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE); Are These Shares Ready to Go Higher? - Aiken Advocate (NASDAQ:RARE)
aikenadvocate.com - January 23 at 7:47 PM
News IconAs Ultragenyx Pharmaceutical In (RARE) Stock Price Rose, Holder Iguana Healthcare Management LLC Has Boosted ... - The Randolph Guide (NASDAQ:RARE)
randolphguide.com - January 23 at 7:47 PM
News IconUltragenyx Pharmaceutical Inc RARE Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:RARE)
www.bioportfolio.com - January 20 at 9:46 PM
News IconRunning on Fumes? Stock Sluggish Out of the Gate: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Aiken Advocate (NASDAQ:RARE)
aikenadvocate.com - January 18 at 8:11 AM
seekingalpha.com logoUltragenyx Pharmaceutical (RARE) presents at J.P. Morgan Healthcare Conference (NASDAQ:RARE)
seekingalpha.com - January 10 at 9:03 PM
bizjournals.com logoTo Emil Kakkis, it's a new day for rare-drug development — BioFlash podcast (NASDAQ:RARE)
feeds.bizjournals.com - January 10 at 11:02 AM
stocksdaily.net logoUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) EPS Projection At $-1.74? - Stocks Daily (NASDAQ:RARE)
www.stocksdaily.net - January 9 at 12:12 AM
rttnews.com logoUltragenyx And KKI Say MAA For KRN23 Filed And Accepted For Review By EMA (NASDAQ:RARE)
www.rttnews.com - January 6 at 1:04 AM
News IconUltragenyx and Kyowa Kirin International Announce Marketing Authorisation Application for KRN23 Filed and Accepted for Review... (NASDAQ:RARE)
www.advfn.com - January 6 at 1:04 AM
capitalcube.com logoUltragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : RARE-US : January 5, 2017 (NASDAQ:RARE)
www.capitalcube.com - January 6 at 1:04 AM
finance.yahoo.com logoUltragenyx and Kyowa Kirin International Announce Marketing Authorization Application for KRN23 Filed and Accepted for Review by European Medicines Agency (NASDAQ:RARE)
finance.yahoo.com - January 5 at 2:13 AM
finance.yahoo.com logoUltragenyx and Kyowa Kirin International Announce Marketing Authorisation Application for KRN23 Filed and Accepted for Review by European Medicines Agency (NASDAQ:RARE)
finance.yahoo.com - January 5 at 2:13 AM
publicnow.com logoUltragenyx and Kyowa Kirin International Announce Marketing Authorisation Application for KRN23 Filed and Accepted for Review by European Medicines Agency(106KB) (NASDAQ:RARE)
www.publicnow.com - January 5 at 2:13 AM
globenewswire.com logoUltragenyx to Present at J.P. Morgan Healthcare Conference - GlobeNewswire (press release) (NASDAQ:RARE)
globenewswire.com - January 4 at 4:08 PM
finance.yahoo.com logoUltragenyx to Present at J.P. Morgan Healthcare Conference (NASDAQ:RARE)
finance.yahoo.com - January 4 at 4:08 PM
investornewswire.com logoUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Records An Impact Score Of 0 - Investor Newswire (NASDAQ:RARE)
www.investornewswire.com - December 27 at 3:15 PM
capitalcube.com logoUltragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : December 23, 2016 (NASDAQ:RARE)
www.capitalcube.com - December 23 at 8:11 AM
capitalcube.com logoETFs with exposure to Ultragenyx Pharmaceutical, Inc. : December 14, 2016 (NASDAQ:RARE)
www.capitalcube.com - December 14 at 8:27 PM
capitalcube.com logoUltragenyx Pharmaceutical, Inc. – Value Analysis (NASDAQ:RARE) : December 13, 2016 (NASDAQ:RARE)
www.capitalcube.com - December 13 at 7:50 PM
capitalcube.com logoUltragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : December 12, 2016 (NASDAQ:RARE)
www.capitalcube.com - December 12 at 9:31 AM
News IconVolatility Levels in Focus for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Marion Business Daily (NASDAQ:RARE)
marionbusinessdaily.com - December 11 at 6:29 PM
News IconStock Watch: Focusing in on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Marion Business Daily (NASDAQ:RARE)
marionbusinessdaily.com - December 11 at 9:19 AM
insidermonkey.com logoHedge Funds Are Dumping Ultragenyx Pharmaceutical Inc (RARE) (NASDAQ:RARE)
www.insidermonkey.com - December 9 at 7:24 PM
News IconFree Cash Flow Score in Focus for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Marion Business Daily (NASDAQ:RARE)
marionbusinessdaily.com - December 9 at 12:55 AM

Social

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Where is Ultragenyx Pharmaceutical's stock going? Where will Ultragenyx Pharmaceutical's stock price be in 2017?

14 equities research analysts have issued 12-month price targets for Ultragenyx Pharmaceutical's stock. Their forecasts range from $64.00 to $109.00. On average, they expect Ultragenyx Pharmaceutical's share price to reach $92.25 in the next twelve months.

When will Ultragenyx Pharmaceutical announce their earnings?

Ultragenyx Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.

What are analysts saying about Ultragenyx Pharmaceutical stock?

Here are some recent quotes from research analysts about Ultragenyx Pharmaceutical stock:

  • Cowen and Company analysts commented, "Ultragenyx reported a Q4 net loss of $71MM and ended the quarter with cash of." (2/17/2017)

  • Jefferies Group LLC analysts commented, "uneventful" 2016 fourth quarter earnings call, as the company is expecting first commercial product by the end of 2017.Wang comments, "RARE 4Q16 EC was largely uneventful. Mgmt highlighted recent clinical progress in multiple programs and potentially first commercial product by YE17. We see overall favorable risk/reward heading into multiple data and regulatory catalysts in 2017, including KRN23 Ph3 data in adult XLH (1H17), BLA filing in the US, CHMP opinion in EU (2H17), Ace-ER Ph3 data in GNE myopathy (2H17)' RARE reported 4Q16 OpEx of $70.6M vs. our/consensus est of $74.8/69.9M. EPS was ($1.75) vs. our/consensus est of ($1.86/1.72). The company ended the quarter with $498.1M cash and guided that the cash should be sufficient to fund all clinical programs through Ph3 studies and potential launch. Mgmt guided to a continual increase in OpEx with a gradually slower YoY growth. Our $109 target is based on probability adjusted DCF. Risks include delay in EU conditional approval, less robust data, toxicity." (2/17/2017)
  • According to Zacks Investment Research, "Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California. " (1/12/2017)

  • Leerink Swann analysts commented, "We maintain our OP rating on RARE with PT $85. A 64.8%/70.6% reduction in uGAGs (p50%/>60% reduction in dermatan and chondroitin sulfate (both uGAGs) within the first 2 weeks that was maintained until 24 weeks. Despite investors’ concerns of a small trial (n=12), 4 mg/kg rhGUS effectively demonstrated its efficacy as an enzyme in removing the accumulated substrate in MPS VII pts. Although the aggregate of functional improvements narrowly missed stat. sig. (p=0.0527), we believe clinical improvements engenderd by rhGUS makes a strong case for the therapy. The summation of scores from functional assessments (including 6-minute walk test/6MWT and visual acuity) showed a positive trend. With regards to the miss on stat. sig., we agree with mgmt. that individual assessments paint a clearer picture of therapeutic benefit in pts. and remind investors that neither regulatory agencies required stat. sig. in earlier discussions. Furthermore, whereas functionality in pts. progressively worsen, noteworthy improvements in 6MWT (especially 60+ meters benefit in 3/9 pts. over 24 weeks) and ~2/3 of pts." (7/15/2016)

Who owns Ultragenyx Pharmaceutical stock?

Ultragenyx Pharmaceutical's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.40%), State Street Corp (3.42%), Columbia Wanger Asset Management LLC (2.88%), Capital Guardian Trust Co. (1.40%), Federated Investors Inc. PA (1.07%) and Brown Advisory Inc. (0.73%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Shalini Sharp, Sunil Agarwal, Theodore Alan Huizenga, Thomas Richard Kassberg and William Aliski.

Who sold Ultragenyx Pharmaceutical stock? Who is selling Ultragenyx Pharmaceutical stock?

Ultragenyx Pharmaceutical's stock was sold by a variety of institutional investors in the last quarter, including Columbia Wanger Asset Management LLC, State Street Corp, FMR LLC, Highland Capital Management LP, Allianz Asset Management AG, Guggenheim Capital LLC, Federated Investors Inc. PA and Trexquant Investment LP. Company insiders that have sold Ultragenyx Pharmaceutical stock in the last year include Emil D Kakkis, Shalini Sharp, Sunil Agarwal and William Aliski.

Who bought Ultragenyx Pharmaceutical stock? Who is buying Ultragenyx Pharmaceutical stock?

Ultragenyx Pharmaceutical's stock was acquired by a variety of institutional investors in the last quarter, including Capital Guardian Trust Co., Fred Alger Management Inc., Teachers Retirement System of The State of Kentucky, Brown Advisory Inc., Russell Investments Group Ltd., Capital International Inc. CA, Dimensional Fund Advisors LP and Capital International Ltd. CA.

How do I buy Ultragenyx Pharmaceutical stock?

Shares of Ultragenyx Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Ultragenyx Pharmaceutical stock cost?

One share of Ultragenyx Pharmaceutical stock can currently be purchased for approximately $78.18.

Ultragenyx Pharmaceutical (NASDAQ:RARE) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Earnings History Chart

Earnings by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Dividend History Chart

Dividend Payments by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Last Updated on 2/23/2017 by MarketBeat.com Staff